OncLive TV

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Eileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

Mohammad Maher Abdul-Hay, MD, discusses the future of targeted therapy in acute lymphoblastic leukemia.

Faith E. Davies, MD, discusses the dosing of carfilzomib in the treatment of patients with multiple myeloma.

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.

Riad Salem, MD, discusses the role of locoregional therapy in hepatocellular carcinoma.

Matthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.

Clara Hwang, MD, discusses the utility of antiandrogens in patients with metastatic prostate cancer.

Alvin H. Schmaier, MD, discusses the secondary management of thrombosis in patients with hematologic malignancies.

Karen L. Reckamp, MD, MS, provides insight on how she is navigating challenges posed by the COVID-19 crisis.

Faith E. Davies, MD, discusses the use of venetoclax as a precision medicine approach in patients with relapsed/refractory multiple myeloma.

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Prapti Patel, MD, discusses data from the MEDALIST trial on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndromes.

Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Dana Chase, MD, FACOG, discusses the safety profile of niraparib as frontline maintenance therapy in ovarian cancer.

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

Vincent Chung, MD, discusses the importance of genomic testing in pancreatic cancer.